SEC Form 4 · accession 0001250853-15-000104
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J Knapp
Officer — General Counsel
Period of report
Dec 18, 2015
Accepted (ET)
Dec 22, 2015 · 8:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $1.50 | Dec 18, 2015 | A | 225,000 | A | — | Dec 18, 2025 | Common Stock | 225,000 | 225,000 | D |
Explanation of responses
- F1Granted pursuant to the Issuer's Amended and Restated 2007 Incentive Plan.
- F2The stock option will vest in 16 equal, quarterly installments over 4 years, beginning 3 months from the date of grant, so long as the Reporting Person remains in the company's continuous employ of the Issuer through the vesting period.